MCID: CNN010
MIFTS: 44

Connective Tissue Benign Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Benign Neoplasm

MalaCards integrated aliases for Connective Tissue Benign Neoplasm:

Name: Connective Tissue Benign Neoplasm 12 15
Soft Tissue Neoplasms 56 45 74
Soft Tissue Benign Neoplasm 12
Neoplasm of Soft Tissues 12
Tumor of the Soft Tissue 12
Neoplasm of Soft Tissue 12
Soft Tissue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060123
MeSH 45 D012983
NCIt 51 C3377
UMLS 74 C0037579

Summaries for Connective Tissue Benign Neoplasm

Disease Ontology : 12 A musculoskeletal system benign neoplasm that is located in connective tissue.

MalaCards based summary : Connective Tissue Benign Neoplasm, also known as soft tissue neoplasms, is related to desmoid tumor and bone benign neoplasm. An important gene associated with Connective Tissue Benign Neoplasm is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Glioblastoma Multiforme. The drugs Docetaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and liver, and related phenotypes are growth/size/body region and behavior/neurological

Related Diseases for Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 desmoid tumor 32.2 CTNNB1 PDGFRB
2 bone benign neoplasm 31.6 CDC73 ENO2 ERCC6 HACD1 USP6
3 dermatofibrosarcoma protuberans 29.8 CD34 PDGFRB SERPINA3
4 gastrointestinal stromal tumor 29.4 CD34 ENO2 PDGFRB
5 fibroma 11.2
6 infantile myofibromatosis 11.2
7 chondrosarcoma, extraskeletal myxoid 11.1
8 spleen angiosarcoma 11.1
9 glomangiosarcoma 11.0
10 undifferentiated embryonal sarcoma of the liver 10.4 MDM2 SERPINA3
11 inflammatory mfh 10.4 MDM2 SERPINA3
12 hemangiopericytoma, malignant 10.3
13 epithelioid leiomyosarcoma 10.3 ENO2 SERPINA3
14 embryonal sarcoma 10.3 CTNNB1 MDM2 SERPINA3
15 goblet cell carcinoid 10.3 CTNNB1 ENO2
16 ossifying fibroma 10.3 CDC73 ERCC6 MDM2
17 fibrosarcoma of bone 10.3 MDM2 PDGFRB SERPINA3
18 osteoblastoma 10.3 CTNNB1 USP6
19 nodular ganglioneuroblastoma 10.2 ENO2 MDM2
20 chondroid lipoma 10.2 ENO2 MDM2
21 skin pilomatrix carcinoma 10.2 CLEC2A CTNNB1
22 heart sarcoma 10.2 ENO2 MDM2 PDGFRB
23 leiomyosarcoma 10.2 ENO2 MDM2 PDGFRB
24 disseminated peritoneal leiomyomatosis 10.2
25 kaposi sarcoma 10.1
26 cellular neurofibroma 10.1 CD34 PDGFRB
27 sclerosing liposarcoma 10.1 CD34 MDM2
28 lung meningioma 10.1 CD34 ENO2
29 mixed liposarcoma 10.1 CD34 MDM2
30 gastric squamous cell carcinoma 10.1 ENO2 SERPINA3
31 psammomatous meningioma 10.0 CD34 CTNNB1 ERCC6
32 plexiform schwannoma 10.0 CD34 ENO2
33 ischemic fasciitis 10.0 CD34 MDM2 USP6
34 cell type benign neoplasm 10.0 CD34 CDC73 CTNNB1
35 pseudosarcomatous fibromatosis 10.0 CD34 CTNNB1 USP6
36 brain cancer 10.0 CTNNB1 ENO2 MDM2 PDGFRB
37 spindle cell liposarcoma 10.0 CD34 MDM2
38 conventional fibrosarcoma 10.0 CD34 ENO2 MDM2
39 muscle cancer 10.0 CD34 ENO2 MDM2
40 liposarcoma 10.0
41 perineurioma 10.0
42 actinomycosis 10.0
43 periosteal osteogenic sarcoma 10.0 CD34 MDM2
44 nervous system cancer 10.0 CD34 ENO2 MDM2
45 giant cell tumor 9.9
46 malignant giant cell tumor 9.9
47 connective tissue cancer 9.9 CD34 ENO2 MDM2 SERPINA3
48 sarcoma 9.8
49 malignant fibroxanthoma 9.8
50 perivascular epithelioid cell tumor 9.8

Graphical network of the top 20 diseases related to Connective Tissue Benign Neoplasm:



Diseases related to Connective Tissue Benign Neoplasm

Symptoms & Phenotypes for Connective Tissue Benign Neoplasm

MGI Mouse Phenotypes related to Connective Tissue Benign Neoplasm:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 AKTIP AMBN CDC73 CTNNB1 ENO2 ERCC6
2 behavior/neurological MP:0005386 10.01 AKTIP CDC73 CTNNB1 ENO2 ERCC6 HBEGF
3 integument MP:0010771 9.86 CARMIL2 CD34 CDC73 CTNNB1 ERCC6 HBEGF
4 craniofacial MP:0005382 9.85 AMBN CDC73 CTNNB1 ENO2 MDM2 PDGFRB
5 muscle MP:0005369 9.7 CDC73 CTNNB1 ERCC6 HACD1 HBEGF MDM2
6 neoplasm MP:0002006 9.43 AMBN CD34 CDC73 CTNNB1 ERCC6 MDM2
7 skeleton MP:0005390 9.23 AKTIP AMBN CDC73 CTNNB1 ERCC6 HBEGF

Drugs & Therapeutics for Connective Tissue Benign Neoplasm

Drugs for Connective Tissue Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 4,Phase 2 114977-28-5 148124
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
3
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Etoposide Approved Phase 3,Phase 1 33419-42-0 36462
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 1 50-18-0, 6055-19-2 2907
9
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
10
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
11
Gemcitabine Approved Phase 3,Phase 1 95058-81-4 60750
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
14
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
15
Emodepside Investigational, Vet_approved Phase 3,Phase 1 155030-63-0
16
Doxil Approved June 1999 Phase 3 31703
17 Antimitotic Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
20 Immunologic Factors Phase 3,Phase 2,Phase 1
21 Etoposide phosphate Phase 3,Phase 1
22 Topoisomerase Inhibitors Phase 3,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 1
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 1
26 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
28
Isophosphamide mustard Phase 3 0
29 Alkylating Agents Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 1
31 Dermatologic Agents Phase 3,Phase 2,Phase 1
32 Keratolytic Agents Phase 3,Phase 1
33 Podophyllotoxin Phase 3,Phase 1 518-28-5
34 Antibodies Phase 3,Phase 1,Phase 2
35 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
36 Immunoglobulins Phase 3,Phase 1,Phase 2
37 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
38 Antiviral Agents Phase 3,Phase 1
39 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 topoisomerase I inhibitors Phase 3
42
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
43
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
44
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
45
Pirfenidone Approved, Investigational Phase 2 53179-13-8 40632
46
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
47
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
48
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
49
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
50
leucovorin Approved Phase 2 58-05-9 143 6006

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment Terminated NCT02441517 Phase 4 Enzalutamide
2 Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
5 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
6 Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905) Not yet recruiting NCT03924895 Phase 3 Pembrolizumab
7 Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) Not yet recruiting NCT03924856 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
8 Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood Terminated NCT00162695 Phase 3 Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
9 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Terminated NCT00870701 Phase 3
10 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
11 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
12 The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors Completed NCT00001189 Phase 2
13 Trabectedin First Line Therapy In Unfit Sarcoma Study Completed NCT02066675 Phase 2 Trabectedin
14 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
15 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Completed NCT00076102 Phase 2 Pirfenidone
16 Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia Completed NCT01445080 Phase 1, Phase 2 Sorafenib Tosylate
17 Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors Recruiting NCT02285439 Phase 1, Phase 2 MEK162
18 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors Recruiting NCT01876082 Phase 2 PAZOPANIB treatment;Active Comparator: Vinblastine and Methotrexate
19 Thermal Ablation and Stereotactic Spine Radiosurgery (SSRS) Recruiting NCT02713269 Phase 2
20 Proton or Photon RT for Retroperitoneal Sarcomas Recruiting NCT01659203 Phase 1, Phase 2
21 Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies Recruiting NCT03217747 Phase 1, Phase 2 Avelumab;Utomilumab;PF-04518600;Cisplatin
22 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
23 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis Active, not recruiting NCT01981551 Phase 2 PF-03084014
24 Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Brain Tumors Completed NCT01698437 Phase 1
25 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors Recruiting NCT03159585 Phase 1 TAEST16001
26 Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Recruiting NCT02441972 Phase 1 18F-Al-NOTA-PRGD2 PET/CT
27 Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
28 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
29 Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma Recruiting NCT03450122 Phase 1 Cyclophosphamide;Immunotherapeutic Combination Product CMB305
30 IACS-010759 in Advanced Cancers Recruiting NCT03291938 Phase 1 IACS-010759
31 Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Recruiting NCT03093909 Phase 1 Gemcitabine
32 Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors Active, not recruiting NCT01628640 Phase 1
33 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Terminated NCT02602067 Phase 1
34 Lenvatinib and Capecitabine in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
35 Navigation Surgery for Bone and Soft Tissue Tumor Unknown status NCT01179698 Not Applicable
36 Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans Unknown status NCT00173355
37 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735
38 Radiofrequency Ablation of Painful Soft Tissue Neoplasms Completed NCT00041886
39 Quantitative MR Biomarkers for Sarcoma Treatment Completed NCT01017978 Not Applicable
40 A New Method: the Third Space Robotic and Endoscopic Cooperative Surgery (TS-RECS) Completed NCT03804762 Not Applicable
41 Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients Completed NCT01276483
42 MR-Guided Laser Ablation of Hepatic Tumors Completed NCT01630239 Early Phase 1
43 Optical Detection of Peripheral Nerve Bundles During Surgery Completed NCT01731379
44 Assessment of Mandibular Bone Invasion With MRI Using SWIFT Completed NCT01817140
45 US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors Recruiting NCT03452644
46 An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry Recruiting NCT02677961
47 Liposomal Bupivacaine (Exparel) in Sarcomas Recruiting NCT03867188 Early Phase 1 Liposomal Bupivacaine
48 Osteoarticular Tumor Characterization by Advanced Imaging Recruiting NCT02895633 Not Applicable
49 Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study Recruiting NCT02557243
50 Incisional Negative Pressure Wound Therapy for Resection of Soft Tissue Tumors Recruiting NCT03900078 Not Applicable

Search NIH Clinical Center for Connective Tissue Benign Neoplasm

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: soft tissue neoplasms

Genetic Tests for Connective Tissue Benign Neoplasm

Anatomical Context for Connective Tissue Benign Neoplasm

MalaCards organs/tissues related to Connective Tissue Benign Neoplasm:

42
Bone, Lung, Liver, T Cells, Skin, Brain, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Benign Neoplasm:

20
Connective Tissue

Publications for Connective Tissue Benign Neoplasm

Articles related to Connective Tissue Benign Neoplasm:

(show top 50) (show all 63)
# Title Authors Year
1
Targeted RNA sequencing: A routine ancillary technique in the diagnosis of bone and soft tissue neoplasms. ( 30350361 )
2019
2
SWI/SNF Complex-Deficient Soft Tissue Neoplasms: A Pattern-Based Approach to Diagnosis and Differential Diagnosis. ( 30709441 )
2019
3
Subcutaneous Phaeohyphomycosis: A Clinical Mimic of Skin and Soft Tissue Neoplasms-A Descriptive Study from India. ( 30105639 )
2018
4
Surgical management of truncal soft tissue sarcoma and other selected soft tissue neoplasms. ( 30173529 )
2018
5
Applications of Ancillary Testing in the Cytologic Diagnosis of Soft Tissue Neoplasms. ( 30190145 )
2018
6
Endometriosis Mimicking Soft-Tissue Neoplasms: A Potential Diagnostic Pitfall. ( 28178719 )
2017
7
Soft Tissue Neoplasms Causing Apparent Venous Thoracic Outlet Syndrome. ( 28259825 )
2017
8
Distinctive Head and Neck Bone and Soft Tissue Neoplasms. ( 28153134 )
2017
9
The presence of neuroendocrine features generates a broad differential diagnosis in the fine-needle aspiration of bone and soft tissue neoplasms. ( 31043241 )
2017
10
CTNNB1 (β-Catenin)-altered Neoplasia: A Review Focusing on Soft Tissue Neoplasms and Parenchymal Lesions of Uncertain Histogenesis. ( 26645457 )
2016
11
Myxoid soft-tissue neoplasms: comprehensive update of the taxonomy and MRI features. ( 25615761 )
2015
12
A new technique for biopsy of soft tissue neoplasms: a preliminary experience using MRI to evaluate bleeding. ( 25901366 )
2015
13
Molecular Pathology of Soft-Tissue Neoplasms and Its Role in Clinical Practice. ( 26068763 )
2015
14
Evaluation of Molecular and Immunohistochemical Adjunct Modalities in the Diagnosis of Soft Tissue Neoplasms. ( 26310271 )
2015
15
Clinical Effectiveness of Robotic Image-Guided Stereotactic Radiosurgery (CyberKnife) in Selected Primary and Secondary Soft Tissue Neoplasms: A Systematic Review. ( 27202159 )
2014
16
Cytotechnologist-attended on-site evaluation of adequacy for fine-needle aspiration of bone and soft tissue neoplasms. ( 31051702 )
2014
17
Sirtuin 1 (SIRT1): a potential immunohistochemical marker and therapeutic target in soft tissue neoplasms with myoid differentiation. ( 23332867 )
2013
18
The role of MRI in image-guided needle biopsy of focal bone and soft tissue neoplasms. ( 23644880 )
2013
19
Sox10 and S100 in the diagnosis of soft-tissue neoplasms. ( 22495377 )
2012
20
En bloc resection of extra-peritoneal soft tissue neoplasms incorporating a type III internal hemipelvectomy: a novel approach. ( 23098421 )
2012
21
Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms. ( 21712686 )
2011
22
Magnetic resonance imaging of benign soft tissue neoplasms in adults. ( 22024295 )
2011
23
Magnetic resonance imaging of malignant soft tissue neoplasms in the adult. ( 22024296 )
2011
24
Mimics of bone and soft tissue neoplasms. ( 22024298 )
2011
25
Dermal and Subcutaneous Plexiform Soft Tissue Neoplasms. ( 26837650 )
2011
26
Benign vs malignant soft tissue neoplasms: limitations of magnetic resonance imaging. ( 20587903 )
2010
27
Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. ( 19851129 )
2009
28
The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms. ( 18162764 )
2008
29
Application of immunohistochemistry to soft tissue neoplasms. ( 18318588 )
2008
30
Re: prevalence and diagnostic significance of fluid-fluid levels in soft-tissue neoplasms. ( 18374727 )
2008
31
Prevalence and diagnostic significance of fluid-fluid levels in soft-tissue neoplasms. ( 17604765 )
2007
32
Altered expression of cell cycle regulatory proteins in benign and malignant bone and soft tissue neoplasms. ( 18019405 )
2007
33
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. ( 16160477 )
2005
34
Divergent differentiation in malignant soft tissue neoplasms: the paradigm of liposarcoma and malignant peripheral nerve sheath tumor. ( 15735851 )
2005
35
Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. ( 15716237 )
2005
36
Cytomorphological study of soft tissue neoplasms: role of fluorescent immunocytochemistry in diagnosis. ( 16181307 )
2005
37
Sonography of the hand: tendon pathology, vascular disease, and soft tissue neoplasms. ( 15558619 )
2004
38
Sonographically guided core needle biopsy of soft tissue neoplasms. ( 15211675 )
2004
39
Primary soft-tissue neoplasms of the foot: the clinicopathologic features of 401 cases. ( 11202765 )
2001
40
Paratesticular soft tissue neoplasms. ( 11202547 )
2000
41
Practical applications of immunohistochemistry in the diagnosis of soft tissue neoplasms. ( 11128833 )
1999
42
Imaging of Soft Tissue Neoplasms in the Adult: Benign Tumors. ( 11387125 )
1999
43
Imaging of Soft Tissue Neoplasms in the Adult: Malignant Tumors. ( 11387126 )
1999
44
Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. ( 9865822 )
1998
45
Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group. ( 9191525 )
1997
46
Imaging of pedal soft tissue neoplasms. ( 7489000 )
1995
47
Imaging methods for assessment of pedal soft-tissue neoplasms. ( 8221543 )
1993
48
Development and optimization of tissue preparative methodology for DNA content analysis of soft tissue neoplasms. ( 8287735 )
1993
49
The efficacy of gallium scintigraphy in detecting malignant soft tissue neoplasms. ( 1731652 )
1992
50
Phenoxyacetic acid herbicides and chlorophenols and the etiology of lymphoma and soft-tissue neoplasms. ( 2485916 )
1989

Variations for Connective Tissue Benign Neoplasm

Copy number variations for Connective Tissue Benign Neoplasm from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13803 1 1 56100000 Amplification Soft tissue tumor
2 21057 1 156500000 172900000 Amplification Soft tissue tumor
3 151970 20 27500000 41700000 Amplification Soft tissue tumor
4 178515 3 74200000 91000000 Amplification Soft tissue tumor
5 206336 6 139000000 161000000 Amplification Soft tissue tumor

Expression for Connective Tissue Benign Neoplasm

Search GEO for disease gene expression data for Connective Tissue Benign Neoplasm.

Pathways for Connective Tissue Benign Neoplasm

Pathways related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.3 CTNNB1 HBEGF MDM2
2 10.84 CTNNB1 MDM2 PDGFRB
3 10.55 CTNNB1 PDGFRB

GO Terms for Connective Tissue Benign Neoplasm

Cellular components related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 AKTIP CARMIL2 CD34 CLEC2A CTNNB1 ENO2
2 cell periphery GO:0071944 8.8 CD34 CTNNB1 ODAM

Biological processes related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to toxic substance GO:0009636 9.33 ERCC6 MDM2 PDGFRB
2 odontogenesis of dentin-containing tooth GO:0042475 9.13 AMBN CTNNB1 ODAM
3 endodermal cell fate commitment GO:0001711 8.62 CDC73 CTNNB1

Sources for Connective Tissue Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....